Paperonium

Skin cancer · Lancet Reg Health Eur · 2024

The paper’s summary: 29.8% had severe drug side effects. That’s really the any-cause rate. Drug-linked: 18.5%.

Drug-linked18.5%Its own results28 of 15129.8%The summaryAny causethe summary used this row45 of 15115%20253035
Drug-linked18.5%Its own results: 28 of 151The summary29.8%Any causethe summary used this row45 of 15115%20253035

Share of the 151 patients with at least one severe health problem

The paper says

A study gave 151 people with advanced skin cancer the drug cemiplimab. A main goal was counting severe side effects: problems doctors judged the drug may have caused. The paper’s summary, the short overview most readers see, reports 68 of them, affecting 29.8% of patients.

Its own data show

The paper’s results give both numbers, but for severe health problems from any cause: 68 problems in 45 of 151 patients (29.8%; some had several). Only 42 of those problems were linked to the drug, in 28 of 151 patients (18.5%). The paper’s table of drug-linked problems also adds up to 42.

A health problem during treatment isn’t always the drug’s doing; doctors judge which ones the drug may have caused. Studies like this show how older, frailer patients cope with a drug. Anyone taking the rate from the summary gets 1.6 times the drug-linked one: the drug looks worse than the paper’s own data show.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol · Lancet Reg Health Eur (2024) · doi:10.1016/j.lanepe.2024.100875